Bullous SDRIFE and Covid‐19

Abstract

Bullous SDRIFE and Covid-19Dear Editor, Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a drug reaction with well-defined criteria and some clinical and histopathological variability, in addition to simultaneous overlapping features with other pharmacological reactions. 1,2 We report a special case of SDRIFE with bullae formation in a patient with severe COVID-19, a situation that is unmatched in the literature. A 53-year-old obese woman with diabetes mellitus, chronic obstructive pulmonary disease, and a diagnosis of COVID-19 made 21 days earlier was admitted to the intensive care unit (ICU) with respiratory failure, bacterial pneumonia (Pseudomonas aeruginosa), intravascular device-related blood-

Symmetrical drug-related intertriginous and flexural exanthema-like rash related to severe acute respiratory syndrome coronavirus 2 infection

“…unclear since in the vast majority of cases a concomitant or previous drug treatment was recorded. [2][3][4][5]7 Additionally, SDRIFE-like reactions related to Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Comirnaty) with skin biopsies showing vacuolar interface dermatitis with mild eosinophilic spongiosis have also been reported. 6 The clinical and evolutive features of reported cases of SDRIFElike eruptions associated with COVID-19 are detailed in Table 1.…”

“…2 Recently, isolated reports of SDRIFE-like eruptions associated with either COVID-19 infection or vaccination have been described. [2][3][4][5][6][7] We report a case of SDRIFE-like eruption related exclusively with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in the absence of any associated drug.…”

“…9,10 Recently, isolated reports of SDRIFE-like rashes associated with either SARS-CoV-2 vaccination or infection have been published. [2][3][4][5][6][7] The real significance of these eruptions as a skin manifestation of COVID-19 disease remains…”